Act as an expert academic nephrologist and research supervisor. I am a DM Nephrology student seeking novel, feasible, and high-impact study topics for my thesis or publication in 2026. Suggest 5 specific clinical research topics which are advanced and very helpful in researchwithin e.g., Acute kidney injury, IgA Nephropathy, or vasculitis ]. For each topic, provide: 1. A potential research title. 2. The primary objective. 3. The recommended study design (e.g., prospective observational, retrospective cohort, randomized trial). 4. A brief note on feasibility at a tertiary care center.
Searching PubMed
AKI to CKD transition biomarkers prognosis
Searching PubMed
IgA nephropathy treatment sparsentan endothelin
Searching PubMed
ANCA vasculitis avacopan complement remission
Searching PubMed
gut microbiome IgA nephropathy galactose deficient
Searching PubMed
SGLT2 inhibitor cardiorenal AKI protection CKD
Searching PubMed
acute kidney injury biomarkers DKK3 TIMP2 IGFBP7 prediction
Searching PubMed
SGLT2 inhibitor acute kidney injury prevention hospitalized
Searching the Web
nephrology thesis topics 2025 2026 novel clinical research AKI IgA vasculitis CKD progression
Here are 5 specific, novel, and feasible clinical research topics for your DM Nephrology thesis or publication in 2026, grounded in the current evidence landscape (including the KDIGO 2025 IgAN/IgAV guideline, the KDIGO 2026 AKI/AKD draft guideline, and recent PubMed literature).
5 High-Impact Nephrology Research Topics for 2026
Topic 1 - AKI to CKD Transition
Research Title:
"Urinary DKK3 and [TIMP-2 x IGFBP7] as Sequential Predictors of AKI-to-CKD Transition in Critically Ill Patients: A Prospective Cohort Study"
Primary Objective:
To evaluate whether urinary Dickkopf-3 (DKK3) at ICU discharge, combined with the cell-cycle arrest biomarker product [TIMP-2 x IGFBP7] measured at 48 hours post-AKI diagnosis, independently predicts the development of CKD (eGFR <60 or >25% decline) at 90 days.
Study Design:
Prospective observational cohort. Enroll consecutive ICU patients who develop AKI (KDIGO stage 1-3). Collect serial urine at 48 h, 7 days, and ICU discharge. Primary endpoint: CKD at 90-day outpatient follow-up. Secondary endpoint: AKI recurrence, 1-year mortality.
Feasibility at a Tertiary Care Center:
ICUs in tertiary centers routinely see 200-400 AKI episodes/year. Urine DKK3 ELISA is commercially available and can be batched (stored at -80°C). [TIMP-2 x IGFBP7] is available as NephroCheck (FDA-cleared). Ethics approval for urine biobanking is straightforward. A 12-18 month enrollment period is realistic. This fills a critical gap highlighted by the 2026 KDIGO AKI/AKD draft guideline - fewer than 30% of AKI survivors who progress to CKD are currently identified before discharge.
Supporting Evidence: PMID 40598328 (Singh et al., Crit Care, 2025 - AKI-biomas study); PMID 42086806 (Jin et al., Pediatr Nephrol, 2026 - biomarker review).
Topic 2 - IgA Nephropathy and Gut-Kidney Axis
Research Title:
"Gut Microbiome Dysbiosis, Serum Galactose-Deficient IgA1 (Gd-IgA1) Levels, and Disease Activity in IgA Nephropathy: A Cross-Sectional Study with Correlation to Oxford MEST-C Score"
Primary Objective:
To characterize gut microbiome composition (16S rRNA sequencing of stool) and serum Gd-IgA1 levels in biopsy-proven IgAN patients, and correlate both with Oxford MEST-C histological score and 24-hour proteinuria at the time of biopsy.
Study Design:
Cross-sectional observational study with prospective sample collection at the time of kidney biopsy. Comparator groups: IgAN patients vs. non-IgAN glomerulonephritis vs. healthy controls. Key measurements: stool 16S rRNA sequencing (Illumina MiSeq platform), serum Gd-IgA1 ELISA, urine proteomics, and Oxford score from renal pathology.
Feasibility at a Tertiary Care Center:
IgAN is the most common primary glomerulonephritis globally - a busy tertiary nephrology unit performing 150-200 biopsies/year can expect 40-60 IgAN diagnoses annually. Stool collection requires only a consent-and-kit protocol. Microbiome sequencing can be outsourced to academic microbiology facilities. The KDIGO 2025 IgAN guideline explicitly identifies gut-kidney axis research as a priority research gap. No pharmacological intervention is needed, keeping cost and regulatory burden minimal.
Supporting Evidence: PMID 39981255 (Yao et al., Front Immunol, 2025); PMID 38402460 (Zhu et al., NDT, 2024 - TLR4/microbiome pathway in IgAN); PMID 41587026 (Stoneman et al., JAMA, 2026 - IgAN review).
Topic 3 - ANCA Vasculitis and Avacopan
Research Title:
"Real-World Outcomes of Avacopan-Based Steroid-Sparing Remission Induction in ANCA-Associated Vasculitis with Severe Renal Involvement (eGFR <20 mL/min): A Retrospective Multicenter Cohort Study"
Primary Objective:
To assess complete remission rate at 26 weeks, renal recovery (eGFR improvement >20%), and serious infection burden in patients with ANCA-associated vasculitis (AAV) and severe renal involvement (eGFR <20 at presentation) treated with avacopan plus rituximab, compared to historical controls treated with high-dose glucocorticoids plus rituximab.
Study Design:
Retrospective multicenter cohort (2-3 tertiary nephrology/rheumatology centers). Cases: AAV patients who received avacopan since its availability (2022 onward). Controls: historical cohort (2018-2022) matched on eGFR, ANCA subtype (MPO vs PR3), and renal histology (focal vs crescentic). Primary outcome: BVAS-based remission at 26 weeks. Secondary: glucocorticoid cumulative dose, infection episodes, dialysis-free survival at 12 months.
Feasibility at a Tertiary Care Center:
ADVOCATE trial (2021) excluded patients with eGFR <15, so this population is understudied. Avacopan has been available in India since 2023-2024, giving sufficient follow-up time in early adopters. Chart review methodology keeps costs low. A multicenter design (linking 2-3 nephrology centers) is feasible through existing DM Nephrology networks. The recent 2025 review (Trivioli et al., Nat Rev Rheumatol, 2025 Jul) and PMID 40814647 (Geetha et al., Kidney Int Rep, 2025) confirm this is an active unanswered question.
Supporting Evidence: PMID 40473820 (advances in AAV treatment, Nat Rev Rheumatol 2025); PMID 42130237 (AAV pipeline, Curr Opin Nephrol Hypertens 2026).
Topic 4 - SGLT2 Inhibitors and Hospital-Acquired AKI
Research Title:
"Effect of Pre-Admission SGLT2 Inhibitor Use on the Incidence and Severity of Hospital-Acquired Acute Kidney Injury in Patients with Type 2 Diabetes: A Propensity Score-Matched Retrospective Cohort Study"
Primary Objective:
To determine whether patients with Type 2 Diabetes Mellitus (T2DM) and CKD G2-G3 who were on SGLT2 inhibitors (empagliflozin or dapagliflozin) prior to hospital admission have a lower incidence of hospital-acquired AKI (KDIGO stage 1 or higher), compared to propensity score-matched T2DM-CKD controls not on SGLT2i, after adjustment for contrast exposure, sepsis, and surgery.
Study Design:
Retrospective propensity score-matched cohort using hospital electronic medical records (EMR). Inclusion: T2DM patients with pre-existing CKD G2-G3 admitted for any indication (2022-2025). Propensity variables: age, eGFR, HbA1c, diabetes duration, concomitant ACEi/ARB use, admission diagnosis. Outcome: AKI incidence, peak creatinine rise, dialysis requirement, length of stay.
Feasibility at a Tertiary Care Center:
This is a chart-review/EMR study - no patient contact or additional samples required. Tertiary hospitals in India admit thousands of diabetic patients annually. With structured EMR access, a dataset of 300-500 matched pairs is achievable within 6-8 months. The question is clinically highly relevant given the 2026 KDIGO cardiorenal controversies guideline and the nuanced picture from PMID 40736512 (Nakao et al., NDT, 2026 - SGLT2i and AKI review). This study has direct clinical impact on "hold or continue" decisions for SGLT2i during hospitalization.
Topic 5 - IgA Nephropathy and Sparsentan/Endothelin Blockade
Research Title:
"Proteinuria Reduction and Short-Term Renal Outcomes with Sparsentan versus Standard-of-Care RAS Blockade in Biopsy-Proven IgA Nephropathy with Persistent Proteinuria: A Prospective Open-Label Randomized Pilot Study"
Primary Objective:
To compare the magnitude of 24-hour proteinuria reduction at 9 months between sparsentan (a dual endothelin-angiotensin receptor antagonist) and maximally tolerated RAS blockade (ACEi/ARB) in patients with biopsy-proven IgAN and persistent proteinuria (>1 g/day), in a South Asian cohort.
Study Design:
Prospective, open-label, parallel-arm randomized pilot RCT (n=40-60; 1:1 allocation). Inclusion: Adults with IgAN, MEST-C T1/T2 or E1, eGFR >30, proteinuria >1 g/day despite RAS blockade for >3 months. Primary endpoint: 24-h proteinuria at 9 months. Secondary: eGFR slope at 12 months, blood pressure, adverse events (edema, hepatotoxicity), serum Gd-IgA1 change, Oxford score stability on repeat biopsy (optional).
Feasibility at a Tertiary Care Center:
Sparsentan received FDA approval in 2023 (PROTECT trial data) and is being studied in post-marketing settings globally. A pilot RCT of this size (40-60 patients) is achievable in 18-24 months at a center performing regular kidney biopsies. The KDIGO 2025 IgAN guideline (Floege et al., Kidney Int 2025) explicitly calls for data on sparsentan in Asian populations where disease phenotype differs. South Asian ethnicity is an underrepresented population in PROTECT. This study would be the first Indian RCT with sparsentan in IgAN and is highly publishable.
Supporting Evidence: PMID 39643698 (Smeijer et al., Nat Rev Nephrol, 2025 - endothelin receptor antagonists in CKD); PMID 39894081 (Floege et al., Kidney Int, 2025 - IgAN new paradigm).
Summary Comparison Table
| # | Domain | Study Type | Approx. Timeline | Key Innovation |
|---|---|---|---|---|
| 1 | AKI-to-CKD transition | Prospective cohort | 18-24 months | Serial DKK3 + [TIMP-2xIGFBP7] prediction model |
| 2 | IgAN - gut axis | Cross-sectional observational | 12-18 months | Microbiome-Gd-IgA1-Oxford score correlation |
| 3 | ANCA vasculitis | Retrospective multicenter cohort | 12-15 months | Avacopan in eGFR <20 (excluded from ADVOCATE) |
| 4 | SGLT2i + hospital AKI | Retrospective EMR cohort | 8-12 months | Fastest feasibility; direct policy impact |
| 5 | IgAN - sparsentan RCT | Open-label pilot RCT | 24-30 months | First South Asian sparsentan RCT; highest impact |
Prioritization Advice
- Fastest to complete: Topic 4 (pure EMR/chart-review, no sample processing)
- Highest publication impact: Topic 5 (pilot RCT) or Topic 3 (fills ADVOCATE trial gap)
- Best for understanding disease biology: Topic 2 (gut-kidney axis) - unique translational angle
- Best for thesis depth: Topic 1 (biomarker study with prospective follow-up and clinical endpoints)
For any of these, your first step should be to check your center's existing biopsy/ICU/EMR database to confirm case volume, then draft a brief concept note for your supervisor. Topics 3 and 4 can both be written up as multicenter retrospective studies, which considerably reduces time to publication.
This is a shared conversation. Sign in to Orris to start your own chat.